Overview

Price chart · mood · technical indicators

VTRS

Viatris Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$15.2079.25%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$8.19$16.47

Current: $15.20

Idea: EMA

1Y Return

+32.6%

Sharpe 3Y

0.69

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

VTRS

+79.25%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—Forward 6.12

EPS (TTM)$-3.00-70.6% YoY

Profit margin-24.6%HEALTHCARE

Market cap$17.51BLarge cap

Wall Street coverage

$15.72median target· current $11.82 (+33.0%)11 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 6.12
PEG ratio: 0.14
P/B: 1.19
P/S (TTM): 1.23
EV/EBITDA: 8.51

Profitability & growth

ROE (TTM): -21.1%
Operating margin: 7.8%
Revenue growth YoY: 5.0%
Dividend yield: 3.2%
Beta: 0.87

Last earnings

Mar 2, 2026 · Estimate $0.53 · Reported $0.57

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Viatris Inc

Company profile

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: ROBERT J. COURY GLOBAL CENTER, CANONSBURG, PA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$17.51B

Shares outstanding$1.16B

52W high$16.33

52W low$7.90

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

VTRS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Viatris Names Paul Campbell Interim Chief Financial Officer

Theodora Mistras to Become Edwards Lifesciences CFO, Succeeding Scott Ullem

Edwards picks Viatris finance chief Doretta Mistras as CFO

Viatris (Nasdaq: VTRS) appoints Paul Campbell as interim CFO

Edwards Lifesciences Announces Appointment of CFO

Viatris CFO Doretta Mistras to leave, Paul Campbell named interim By Investing.com

Viatris Announces Chief Financial Officer Transition

Viatris Announces Chief Financial Officer Transition

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Earnings Preview: Viatris to Report Financial Results on May 07

Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report

Jennison Associates LLC Has $110.78 Million Stock Holdings in CVS Health Corporation $CVS

Viatris presents data on low-dose contraceptive patch at ACOG

Weekly birth control patch data gets 6 slots at major OB-GYN meeting

Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30?

Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS)

New Halozyme (NASDAQ: HALO) CFO lands $7.2M equity and cash package

About Viatris Inc

Classification

Company profile

VTRS

Market Comparison

VTRS Market Analysis

Overview

VTRS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Viatris Names Paul Campbell Interim Chief Financial Officer

Theodora Mistras to Become Edwards Lifesciences CFO, Succeeding Scott Ullem

Edwards picks Viatris finance chief Doretta Mistras as CFO

Viatris (Nasdaq: VTRS) appoints Paul Campbell as interim CFO

Edwards Lifesciences Announces Appointment of CFO

Viatris CFO Doretta Mistras to leave, Paul Campbell named interim By Investing.com

Viatris Announces Chief Financial Officer Transition

Viatris Announces Chief Financial Officer Transition

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Viatris Contraceptive Patch Data Puts Women’s Health Growth Story In Focus

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Earnings Preview: Viatris to Report Financial Results on May 07

Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report

Jennison Associates LLC Has $110.78 Million Stock Holdings in CVS Health Corporation $CVS

Viatris presents data on low-dose contraceptive patch at ACOG

Weekly birth control patch data gets 6 slots at major OB-GYN meeting

Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30?

Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS)

New Halozyme (NASDAQ: HALO) CFO lands $7.2M equity and cash package

About Viatris Inc

Classification

Company profile

VTRS

Market Comparison